The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company’s EBITDA margin remained resilient above 20%
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Subscribe To Our Newsletter & Stay Updated
